Allergan plc announced that the US Food and Drug Administration (FDA) has accepted for review the company’s supplemental New Drug Application (sNDA) for Avycaz (ceftazidime and avibactam), seeking to expand the label to include the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI), in combination with metronidazole, in paediatric patients 3 months to less than 18 years of age.
